MRUS Live signaler | Maksimer profitt med Getagraph.com

KJøP 114372 min ago

@ $42.61

Utstedt: 14 feb 2024 @ 20:47

Avkastning: 13.49%

Forrige signal: feb 13 - 21:34

Forrige signal: Selg

Avkastning: 1.44 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	286 201
Gjennomsnittsvolum	637 417
Markedsverdi	2.80B
EPS	$-1.040 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.12
ATR14	$0.0570 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-19	Shuman Harry	Sell	115	Common Shares
2023-12-15	Silverman Peter B.	Buy	1 286	Common Shares
2023-12-15	Silverman Peter B.	Buy	21 100	Common Shares
2023-12-15	Silverman Peter B.	Sell	21 100	Share Option (right to buy)
2023-12-15	Silverman Peter B.	Sell	22 386	Common Shares

INSIDER POWER
69.18
Last 99 transactions
Buy: 2 523 001 \| Sell: 3 636 553

Volum Korrelasjon

Lang: -0.24 (neutral)

Kort: -0.16 (neutral)

Signal:(35.527) Neutral

Merus NV Korrelasjon

10 Mest positive korrelasjoner
HOWL	0.948
YMAB	0.946
CGEM	0.943
SLN	0.941
NVCN	0.937
REYN	0.935
KYMR	0.934
BRIVU	0.931
PPH	0.929
VERA	0.929

10 Mest negative korrelasjoner
WINT	-0.939
REVB	-0.937
VALN	-0.937
BIOL	-0.933
SRNGW	-0.933
VRM	-0.931
LHDX	-0.931
SGML	-0.93
TENX	-0.928
IMV	-0.924

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Merus NV Korrelasjon - Valuta/Råvare

-0.20
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.47
( neutral )

-0.41
( neutral )

Merus NV Økonomi

Annual	2023
Omsetning:	$43.95M
Bruttogevinst:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2023
Omsetning:	$43.95M
Bruttogevinst:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2022
Omsetning:	$41.59M
Bruttogevinst:	$29.60M (71.19 %)
EPS:	$-2.92

FY	2021
Omsetning:	$49.11M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.730

Financial Reports:

No articles found.

Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.